Hims & Hers Health faces a 99.6% market-implied probability of missing consensus estimates for its Q2 2026 results due to persistent profitability challenges despite revenue expansion. Analysts project EPS around -$0.05 amid higher operating costs and investments in weight-loss offerings, following the Q1 2026 miss where actual EPS of -$0.40 fell well short of the +$0.04 consensus. Revenue growth to an expected $680–713 million range reflects subscriber gains near 2.9 million, yet margin pressure from competitive dynamics and guidance updates has reinforced trader skepticism. The earnings release scheduled for August 10 could still shift odds if results exceed lowered expectations or management signals improved Adjusted EBITDA trajectory.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于<1% 概率
$6,522 交易量
$6,522 交易量
2026-08-10
<1% 概率
$6,522 交易量
$6,522 交易量
2026-08-10
As of market creation, Hims & Hers Health is estimated to release earnings on August 10, 2026. The Street consensus estimate for Hims & Hers Health's GAAP EPS for the relevant quarter is $-0.05 as of market creation. This market will resolve to "Yes" if Hims & Hers Health reports GAAP EPS greater than $-0.05 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Hims & Hers Health faces a 99.6% market-implied probability of missing consensus estimates for its Q2 2026 results due to persistent profitability challenges despite revenue expansion. Analysts project EPS around -$0.05 amid higher operating costs and investments in weight-loss offerings, following the Q1 2026 miss where actual EPS of -$0.40 fell well short of the +$0.04 consensus. Revenue growth to an expected $680–713 million range reflects subscriber gains near 2.9 million, yet margin pressure from competitive dynamics and guidance updates has reinforced trader skepticism. The earnings release scheduled for August 10 could still shift odds if results exceed lowered expectations or management signals improved Adjusted EBITDA trajectory.
As of market creation, Hims & Hers Health is estimated to release earnings on August 10, 2026. The Street consensus estimate for Hims & Hers Health's GAAP EPS for the relevant quarter is $-0.05 as of market creation. This market will resolve to "Yes" if Hims & Hers Health reports GAAP EPS greater than $-0.05 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
市场开放时间： Jul 27, 2026, 10:09 PM ET
交易量
$6,522结束日期
2026-08-10市场开放时间
Jul 27, 2026, 10:09 PM ET已提议结果: No
无争议
最终结果: No
As of market creation, Hims & Hers Health is estimated to release earnings on August 10, 2026. The Street consensus estimate for Hims & Hers Health's GAAP EPS for the relevant quarter is $-0.05 as of market creation. This market will resolve to "Yes" if Hims & Hers Health reports GAAP EPS greater than $-0.05 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Hims & Hers Health faces a 99.6% market-implied probability of missing consensus estimates for its Q2 2026 results due to persistent profitability challenges despite revenue expansion. Analysts project EPS around -$0.05 amid higher operating costs and investments in weight-loss offerings, following the Q1 2026 miss where actual EPS of -$0.40 fell well short of the +$0.04 consensus. Revenue growth to an expected $680–713 million range reflects subscriber gains near 2.9 million, yet margin pressure from competitive dynamics and guidance updates has reinforced trader skepticism. The earnings release scheduled for August 10 could still shift odds if results exceed lowered expectations or management signals improved Adjusted EBITDA trajectory.
As of market creation, Hims & Hers Health is estimated to release earnings on August 10, 2026. The Street consensus estimate for Hims & Hers Health's GAAP EPS for the relevant quarter is $-0.05 as of market creation. This market will resolve to "Yes" if Hims & Hers Health reports GAAP EPS greater than $-0.05 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If Hims & Hers Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
交易量
$6,522结束日期
2026-08-10市场开放时间
Jul 27, 2026, 10:09 PM ET已提议结果: No
无争议
最终结果: No
Hims & Hers Health faces a 99.6% market-implied probability of missing consensus estimates for its Q2 2026 results due to persistent profitability challenges despite revenue expansion. Analysts project EPS around -$0.05 amid higher operating costs and investments in weight-loss offerings, following the Q1 2026 miss where actual EPS of -$0.40 fell well short of the +$0.04 consensus. Revenue growth to an expected $680–713 million range reflects subscriber gains near 2.9 million, yet margin pressure from competitive dynamics and guidance updates has reinforced trader skepticism. The earnings release scheduled for August 10 could still shift odds if results exceed lowered expectations or management signals improved Adjusted EBITDA trajectory.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题